NCT04886271 2026-04-15
Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase 2 Completed
Clinical Trials
795 trialsNCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT04911907 2026-04-03
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2 Completed
NCT03744468 2026-04-02
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
BeOne Medicines
Phase 1/2 Completed
NCT04303858 2026-04-01
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT05848466 2026-03-30
Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients
Bio-Thera Solutions
Phase 1 Completed
NCT04380753 2026-03-25
AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
Amgen
Phase 1 Completed
NCT07492173 2026-03-25
Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans
Shandong New Time Pharmaceutical Co., LTD
Phase NA Completed
NCT04158336 2026-03-18
A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Completed
NCT06056024 2026-03-17
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
Boehringer Ingelheim
Phase 1 Completed
NCT04261413 2026-03-11
Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors
RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
Phase 1 Completed
NCT05735366 2026-03-10
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
Chugai Pharmaceutical
Phase 1 Completed
NCT06242691 2026-03-06
MK-1200-002
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT02617277 2026-03-04
Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT05800964 2026-02-17
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT02499328 2026-02-11
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
AstraZeneca
Phase 1/2 Completed
NCT05661578 2026-02-09
SKYSCRAPER-11
Hoffmann-La Roche
Phase 2 Completed
NCT02122913 2026-02-05
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
Bayer
Phase 1 Completed
NCT05372367 2026-02-03
A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor
Boehringer Ingelheim
Phase 1 Completed
NCT05419375 2026-02-03
Screening Study for Participants With Malignant Tumors
Hoffmann-La Roche
Phase 2 Completed
NCT04504942 2026-01-23
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
CytoDyn, Inc.
Phase 2 Completed
NCT05136677 2026-01-23
CheckMate 6DW
Bristol-Myers Squibb
Phase 2 Completed
NCT03834272 2026-01-16
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Lumicell, Inc.
Phase 1/2 Completed
NCT04587479 2026-01-13
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1 Completed
NCT04501276 2026-01-08
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
Adagene Inc
Phase 1 Completed
NCT03905148 2026-01-07
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
BeOne Medicines
Phase 1 Completed
NCT04175847 2026-01-07
A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Completed
NCT06130722 2026-01-07
First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study
Suzhou Forlong Biotechnology Co., Ltd
Phase 1 Completed
NCT04617314 2026-01-06
A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
Phase 1 Completed
NCT05174585 2026-01-06
JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT05378737 2026-01-06
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection
Bio-Thera Solutions
Phase 1 Completed
NCT05774873 2026-01-06
The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Completed
NCT05864573 2026-01-05
Study of ZGGS15 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Completed
NCT05307874 2025-12-24
EVICTION-2
ImCheck Therapeutics
Phase 1/2 Completed
NCT04936178 2025-12-22
A Study of NB003 in Patients With Advanced Malignancies
Ningbo Newbay Technology Development Co., Ltd
Phase 1 Completed
NCT05508334 2025-12-22
A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours
RemeGen Co., Ltd.
Phase 1/2 Completed
NCT05240898 2025-12-18
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT05287399 2025-12-18
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
Ascletis Pharma Inc
Phase 1 Completed
NCT04381650 2025-12-10
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Completed
NCT05105971 2025-12-08
Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China
Bio-Thera Solutions
Phase 1 Completed
NCT05155722 2025-12-08
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors
Bio-Thera Solutions
Phase 1 Completed
NCT05387928 2025-12-05
A Study of KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Completed
NCT05549804 2025-12-05
A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Completed
NCT05021120 2025-12-04
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours
Akeso
Phase EARLY_PHASE1 Completed
NCT05134948 2025-12-03
RELATIVITY 059
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05795595 2025-11-26
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics
Phase 1/2 Completed
NCT05991349 2025-11-25
A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Completed
NCT06001580 2025-11-21
A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors
BioRay Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT06170190 2025-11-17
A Multicentre,Study of IBI133 in Subjects WithUnresectable, Locally Advanced or Metastatic SolidTumours
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Completed